{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:38:34Z","timestamp":1756384714502,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>Urinary incontinence, the involuntary leakage of urine, can result from abnormalities of the urinary tract or may be caused by other conditions and is sub-divided into a number of classifications including stress incontinence and urge urinary incontinence.<jats:sup>1<\/jats:sup> Urge urinary incontinence (UUI) is involuntary urine leakage accompanied by urgency of micturition.<jats:sup>2<\/jats:sup> Overactive bladder (OAB) syndrome is defined as urgency occurring with or without UUI and usually occurs with frequency and nocturia.<jats:sup>1<\/jats:sup> Wet OAB is associated with UUI, while dry OAB is not associated with incontinence. Current drug therapy for OAB involves the use of an antimuscarinic drug, of which there are a number available, such as oxybutynin, darifenacin, solifenacin and tolterodine.<jats:sup>1,3<\/jats:sup> \u25bcMirabegron is the first of a new class of drug, beta-3-adrenoreceptor agonists, licensed for symptomatic treatment of urgency, increased micturition frequency and\/or urgency incontinence as may occur in adult patients with OAB syndrome.<jats:sup>4<\/jats:sup> Here we review the evidence for mirabegron.<\/jats:p>","DOI":"10.1136\/dtb.2013.8.0196","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T09:53:51Z","timestamp":1376560431000},"page":"90-92","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["\u25bcMirabegron for overactive bladder syndrome"],"prefix":"10.1136","volume":"51","member":"239","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"2025082701530888000_51.8.90.1","unstructured":"National Collaborating Centre for Women's and Children's Health, 2006. Urinary incontinence. The management of urinary incontinence in women [online]. Available: http:\/\/www.nice.org.uk\/nicemedia\/live\/10996\/30281\/30281.pdf [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.2","unstructured":"National Institute for Health and Care Excellence Clinical Knowledge Summaries, 2013. Urinary incontinence in women [online]. Available: http:\/\/cks.nice.org.uk\/incontinence-urinary-in-women [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.3","unstructured":"Joint Formulary Committee. British National Formulary. Edition 65 March\u2014September 2013. London: BMJ Group and Pharmaceutical Press, March 2013."},{"key":"2025082701530888000_51.8.90.4","unstructured":"Betmiga 25mg and 50mg prolonged-release tablets. Summary of Product Characteristics, EU. Astellas Pharma Ltd, January 2013."},{"key":"2025082701530888000_51.8.90.5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14740338.2011.542146","article-title":"Mirabegron: a safety review","volume":"10","author":"Tyagi P et al","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"2025082701530888000_51.8.90.6","unstructured":"National Institute for Health and Care Excellence, 2006. CG40 Urinary incontinence: The management of urinary incontinence in women [online]. Available: http:\/\/publications.nice.org.uk\/urinary-incontinence-cg40\/guidance [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.7","unstructured":"National Institute for Health and Care Excellence, 2013. Urinary incontinence [online]. Available: http:\/\/guidance.nice.org.uk\/CG\/WaveR\/101 [Accessed 24 July 203]."},{"key":"2025082701530888000_51.8.90.8","unstructured":"National Institute for Health and Care Excellence, 2010. The management of lower urinary tract symptoms in men [online]. Available: http:\/\/publications.nice.org.uk\/lower-urinary-tract-symptoms-cg97\/ [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.021"},{"key":"2025082701530888000_51.8.90.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"2025082701530888000_51.8.90.11","unstructured":"European Medicines Agency, 2011. Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence (draft) [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/11\/WC500117971.pdf [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.12","unstructured":"ClinicalTrials.gov, 2012. A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN) [online]. Available: http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00912964 [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"2025082701530888000_51.8.90.14","unstructured":"European Medicines Agency, 2012. Assessment report. Betmiga. Procedure no. EMEA\/H\/C\/002388 [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002388\/WC500137308.pdf [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.048"},{"key":"2025082701530888000_51.8.90.16","unstructured":"Committee for Proprietary Medicinal Products, 2002. Note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003350.pdf [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.17","unstructured":"National Institute for Health and Care Excellence, 2013. Overactive bladder\u2014mirabegron [ID542] [online]. Available: http:\/\/guidance.nice.org.uk\/?action=byID&o=13828 [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.18","unstructured":"Scottish Medicines Consortium, 2013. Mirabegron 25mg and 50mg prolonged-release tablets (Betmiga(R)). SMC No. (862\/13) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/862_13_mirabegron_Betmiga\/mirabegron_Betmiga [Accessed 24 July 2013]."},{"key":"2025082701530888000_51.8.90.19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"Br J Urol"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2013.8.0196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:53:20Z","timestamp":1756284800000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2013.8.0196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,15]]},"published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1136\/dtb.2013.8.0196"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2013.8.0196","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}